Our startup company, Phenotips (formerly Gene42), announced in September, 2021, that it raised C$2.5M in its first round of financing. TIAP was an early investor and most recently, in this round, participated with additional $100K through its FedDev program. This brings TIAP's total investment as of September 2021 to $300K. Read more about the financing round here.
Phenotips has developed the world’s first "Genomic Health Record,” which offers software to standardize and share genomic medicine workflows. It is now translated into 5 ...
On October 9, 2020, the Honourable Mélanie Joly, Minister of Economic Development and Official Languages and Minister responsible for the Federal Economic Development Agency for Southern Ontario (FedDev Ontario) announced a FedDev Ontario contribution of $6.5 million to Toronto Innovation Acceleration Partners. Read more here: https://bit.ly/3nBEXDR
Under this Agreement, TIAP has to date made the following investments in our portfolio startup companies:
Bitnobi - $15,000, April 1, 2019
Bright Angel Therapeutics - $30,000, August 2, 2019 and $70,000, December 23, 2020
Elarex (McMaster University) - $50,000, ...
Mechelen, Belgium and Toronto, Canada; 15 January 2020, 7.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) and Fibrocor Therapeutics Inc. (Fibrocor) today announced an expanded collaboration focused on novel targets in fibrosis, with Galapagos taking an equity stake in Fibrocor.
Fibrocor is a privately held Canadian company specializing in the development of tissue-specific therapeutics to treat fibrotic diseases of the kidney, liver, lung and other organs. To date, the company has successfully identified a suite of novel targets in fibrosis through ...
TIAP and DAYLI Partners, a leading biotech venture caital firm in South Korea, are collaborating on the creation of a new venture capital fund focused on biotech and health sciences in Canada. The joint investment team will identify & invest in seed stage companies primarily in Ontario with a portion of the fund allocated to Korean companies with high potential to expand to Ontario. Read more here: http://bit.ly/35FH40K
TORONTO, Oct. 3, 2019 /PRNewswire/ -- AmacaThera Inc. (www.amacathera.ca) is pleased to announce the closing of its US $3.6M seed financing round. A first close of the round was led by Sprout BioVentures/ Viva Biotech with participation from Grey Sky Venture Partners, and the round was recently completed with an investment by Toronto-based Lumira Ventures.
Commenting on the closing of the round, Dr. Molly Shoichet, Ph.D., Co-Founder and Chief Scientific Officer of AmacaThera stated: "We are thrilled to have the Lumira team as part ...
TORONTO (March 17, 2016) — QD Solar, a Canadian technology company created by the University of Toronto (U of T) and MaRS Innovation, has received $2.55 million from the Sustainable Development Technology Canada (SDTC).
QD Solar’s funding — announced March 4, 2016 in Edmonton, Alberta by the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development — will galvanize a larger $8.7 million project to revolutionize conventional solar panels that waste a large portion of the available energy in sunlight because ...
MaRS Innovation portfolio company completing Phase 1 human clinical trial of drug to prevent dermal scarring
VANCOUVER (February 16, 2016) — Accel-Rx Health Sciences Accelerator (Accel-Rx), a Centre of Excellence for the Commercialization of Research (CECR), and its partner BDC Capital today announced their second joint investment in ScarX Therapeutics, a Canadian biotechnology company commercializing innovative treatments for dermal scarring (fibrosis).
Accel-Rx and BDC Capital, and other investors including MaRS Innovation, have invested a total of $2 million in ScarX. This investment will ...
Applications for next MSc PoP granting round being accepted until February 25, 2016
TORONTO (January 26, 2016) — Nine Ontario-based medical research projects built on great science with potential for significant economic impact are advancing a step closer to market entry thanks to funding from Ontario Centres of Excellence’s Medical Sciences Proof-of-Principle (MSc PoP) program. The projects range from cancer to heart disease to sleep apnea in children.
Applications for the next MSc PoP granting round are open until March 4, 2016. To ...